Desarrollo y aplicaciones de un modelo de crecimiento para plantaciones de Pinus radiata D. Don en El Bierzo (León)

A dynamic growth model for Pinus radiata D. Don plantations in El Bierzo (Spain) was developed with data from two inventories of permanent plots, of between 7 and 36 years old, established by the University of León. In this model, stand conditions at any point in time are defined by three state variables (stand basal area, number of trees per hectare and dominant height).Themodel includes three transition functions derived by the generalized algebraic difference approach to enable projection of the state variables at any particular time. Once they are known, the number of trees in each diameter class is estimated with a distribution function, by recovery of the parameters of theWeibull function by use of the moments method. Finally, a generalized height-diameter function and a taper function allow estimation of total or merchantable stand volume. The model provides satisfactory predictions for a time interval of three years. Simulation of the growth of four stands under two silvicultural regimes and two different sites confirm that the estimates provided by the overall model adequately represent the effects of both stand density and site quality. Other applications for the model are analysed and discussed.Se ha desarrollado un modelo dinámico de crecimiento para plantaciones de Pinus radiata D. Don en El Bierzo (León) a partir de datos de dos inventarios de parcelas permanentes, de entre 7 y 36 años de edad, establecidas por la Universidad de León. En este modelo, las condiciones del rodal en un instante dado están definidas por tres variables de estado (área basimétrica, número de pies por hectárea y altura dominante). El modelo incluye tres funciones de transición obtenidas mediante la metodología de ecuaciones en diferencias algebraicas generalizadas que permite la proyección de las variables de estado a un determinado instante en el tiempo. Una vez conocidas las variables de estado, una función de distribución estima el número de pies en cada clase diamétrica mediante la metodología de recuperación de los parámetros de la función deWeibull usando el método de los momentos. Finalmente, una función de altura-diámetro generalizada y una función de perfil de tronco permiten la estimación del volumen total o comercial del rodal. El modelo proporciona predicciones satisfactorias para un intervalo de proyección de tres años. La simulación del crecimiento de cuatro rodales bajo dos regímenes selvícolas distintos y dos calidades de estación diferentes corrobora que las estimaciones proporcionadas por el modelo global representan adecuadamente los efectos de la densidad de la masa y la calidad de la estación. Finalmente se analizan y discuten otras aplicaciones del modelo elaborado

Improving the Anaerobic Digestion of Wine-Industry Liquid Wastes: Treatment by Electro-Oxidation and Use of Biochar as an Additive

Wine lees have a great potential to obtain clean energy in the form of biogas through anaerobic digestion due to their high organic load. However, wine lees are a complex substrate and may likely give rise to instabilities leading to failure of the biological process. This work analysed the digestion of wine lees using two dierent approaches. First, electro-oxidation was applied as pre-treatment using boron-doped diamond-based electrodes. The voltage was 25 V and dierent treatment times were tested (ranging from 0.08 to 1.5 h) at 25 C. Anaerobic digestion of wine lees was evaluated in batch tests to investigate the eect of electro-oxidation on biogas yield. Electro-oxidation exhibited a significant positive eect on biogas production increasing its value up to 330 L kg1 of volatile solids after 1.5 h of treatment, compared to 180 L kg1 of volatile solids measured from raw wine lees. As a second approach, the addition of biochar to the anaerobic digestion of wine lees was investigated; in the experimental conditions considered in the present study, the addition of biochar did not show any positive eect on anaerobic digestion performance

Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure

Intraventricular conduction defects (IVCDs) can impair prognosis of heart failure (HF), but their specific impact is not well established. This study aimed to analyse the clinical profile and outcomes of HF patients with LBBB, right bundle branch block (RBBB), left anterior fascicular block (LAFB), and no IVCDs. Clinical variables and outcomes after a median follow-up of 21 months were analysed in 1762 patients with chronic HF and LBBB (n = 532), RBBB (n = 134), LAFB (n = 154), and no IVCDs (n = 942). LBBB was associated with more marked LV dilation, depressed LVEF, and mitral valve regurgitation. Patients with RBBB presented overt signs of congestive HF and depressed right ventricular motion. The LAFB group presented intermediate clinical characteristics, and patients with no IVCDs were more often women with less enlarged left ventricles and less depressed LVEF. Death occurred in 332 patients (interannual mortality = 10.8%): cardiovascular in 257, extravascular in 61, and of unknown origin in 14 patients. Cardiac death occurred in 230 (pump failure in 171 and sudden death in 59). An adjusted Cox model showed higher risk of cardiac death and pump failure death in the LBBB and RBBB than in the LAFB and the no IVCD groups. LBBB and RBBB are associated with different clinical profiles and both are independent predictors of increased risk of cardiac death in patients with HF. A more favourable prognosis was observed in patients with LAFB and in those free of IVCDs. Further research in HF patients with RBBB is warranted

Multiancestry analysis of the HLA locus in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes

Across multiancestry groups, we analyzed Human Leukocyte Antigen (HLA) associations in over 176,000 individuals with Parkinson’s disease (PD) and Alzheimer’s disease (AD) versus controls. We demonstrate that the two diseases share the same protective association at the HLA locus. HLA-specific fine-mapping showed that hierarchical protective effects of HLA-DRB1*04 subtypes best accounted for the association, strongest with HLA-DRB1*04:04 and HLA-DRB1*04:07, and intermediary with HLA-DRB1*04:01 and HLA-DRB1*04:03. The same signal was associated with decreased neurofibrillary tangles in postmortem brains and was associated with reduced tau levels in cerebrospinal fluid and to a lower extent with increased Aβ42. Protective HLA-DRB1*04 subtypes strongly bound the aggregation-prone tau PHF6 sequence, however only when acetylated at a lysine (K311), a common posttranslational modification central to tau aggregation. An HLA-DRB1*04-mediated adaptive immune response decreases PD and AD risks, potentially by acting against tau, offering the possibility of therapeutic avenues

CCD CBERS and ASTER data in dasometric characterization of Pinus radiata D. Don (north-western Spain)

A Chinese-Brazilian Earth Resources Satellite (CBERS) and an Advanced Spaceborne Thermal Emission and Reflection Radiometer (ASTER) scenes coupled with ancillary georeferenced data and field survey were employed to examine the potential of the remote sensing data in stand basal area, volume and aboveground biomass assessment over large areas of Pinus radiata D. Don plantations in Northwestern Spain. Statistical analysis proved that the near infrared band and the shade fraction image showed significant correlation coefficients with all stand variables considered. Predictive models were accordingly selected and utilized to undertake the spatial distribution of stand variables in radiata stands delimited by the National Forestry Map. The study reinforces the potentiality of remote sensing techniques in a cost-effective assessment of forest systems

Quantification of energy transfer processes in LiLa9(SiO4)6O2:Er3+/Yb3+ under selective Er3+excitation

The energy transfer mechanisms between Er3+ and Yb3+ ions have been investigated in LiLa9(SiO4)6O2 under selective Er3+ excitation. IR emission spectra, measured in the CW excitation regime, were used to establish a relationship between the macroscopic transfer and back transfer parameters. These measurements were combined with the results obtained under pulsed excitation to quantify the absolute values of transfer (Yb3+ Er3+) and back transfer coefficients (Er3+ Yb3+), C25 = 9.5 × 10?17 cm3s?1 and C52 = 1.4 × 10?17 cm3s?1, respectively. Additionally, it has been observed an energy transfer that reduces the quantum efficiency of the green emitting Er3+ levels. The corresponding macroscopic coefficient has been also determined (CGQ = 6.1 × 10?17 cm3s?1). © 2014 Optical Society of America

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to <60 mL/min per 1·73 m2 and ≥60 mL/min per 1·73 m2) and urine protein excretion at screening (≤1·75 g/day and >1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein–creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein–creatinine ratio was statistically significantly greater in the sparsentan group (–49·8%) than the irbesartan group (–15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51–0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics